Journal article

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

Hepatology (Baltimore, Md.), 2026 Aug 3. Noureddin M, Sanyal AJ, Bedossa P and 15 others.

Study type

Journal article

Subjects

Not classified in PubMed MeSH

Journal

Hepatology (Baltimore, Md.)

Published

2026 Aug 3

PubMed

PMID 42545725 ↗

DOI

10.1097/HEP.0000000000001825 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Survodutide →

Other papers on Survodutide

Randomized controlled trial · 2026

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Randomized controlled trial · 2026

Survodutide Once Weekly for the Treatment of Adults with Obesity

Randomized controlled trial · 2024

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page